GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ResMed Inc (FRA:RMEA) » Definitions » E10

ResMed (FRA:RMEA) E10 : €0.46 (As of Dec. 2024)


View and export this data going back to 2012. Start your Free Trial

What is ResMed E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

ResMed's adjusted earnings per share data for the three months ended in Dec. 2024 was €0.223. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €0.46 for the trailing ten years ended in Dec. 2024.

During the past 12 months, ResMed's average E10 Growth Rate was 15.60% per year. During the past 3 years, the average E10 Growth Rate was 15.20% per year. During the past 5 years, the average E10 Growth Rate was 14.50% per year. During the past 10 years, the average E10 Growth Rate was 12.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of ResMed was 30.10% per year. The lowest was 10.90% per year. And the median was 18.40% per year.

As of today (2025-03-24), ResMed's current stock price is €20.00. ResMed's E10 for the quarter that ended in Dec. 2024 was €0.46. ResMed's Shiller PE Ratio of today is 43.48.

During the past 13 years, the highest Shiller PE Ratio of ResMed was 102.35. The lowest was 33.33. And the median was 51.11.


ResMed E10 Historical Data

The historical data trend for ResMed's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ResMed E10 Chart

ResMed Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.22 0.24 0.33 0.35 0.41

ResMed Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.37 0.38 0.41 0.40 0.46

Competitive Comparison of ResMed's E10

For the Medical Instruments & Supplies subindustry, ResMed's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ResMed's Shiller PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ResMed's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where ResMed's Shiller PE Ratio falls into.



ResMed E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ResMed's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=0.223/133.1571*133.1571
=0.223

Current CPI (Dec. 2024) = 133.1571.

ResMed Quarterly Data

per share eps CPI Adj_EPS
201503 0.059 99.621 0.079
201506 0.054 100.684 0.071
201509 0.052 100.392 0.069
201512 0.062 99.792 0.083
201603 0.057 100.470 0.076
201606 0.053 101.688 0.069
201609 0.048 101.861 0.063
201612 0.051 101.863 0.067
201703 0.058 102.862 0.075
201706 0.063 103.349 0.081
201709 0.050 104.136 0.064
201712 0.006 104.011 0.008
201803 0.062 105.290 0.078
201806 0.065 106.317 0.081
201809 0.063 106.507 0.079
201812 0.076 105.998 0.095
201903 0.065 107.251 0.081
201906 0.042 108.070 0.052
201909 0.075 108.329 0.092
201912 0.099 108.420 0.122
202003 0.101 108.902 0.123
202006 0.108 108.767 0.132
202009 0.104 109.815 0.126
202012 0.101 109.897 0.122
202103 -0.045 111.754 -0.054
202106 0.110 114.631 0.128
202109 0.118 115.734 0.136
202112 0.121 117.630 0.137
202203 0.111 121.301 0.122
202206 0.126 125.017 0.134
202209 0.144 125.227 0.153
202212 0.144 125.222 0.153
202303 0.148 127.348 0.155
202306 0.144 128.729 0.149
202309 0.140 129.860 0.144
202312 0.130 129.419 0.134
202403 0.188 131.776 0.190
202406 0.184 132.554 0.185
202409 0.190 133.029 0.190
202412 0.223 133.157 0.223

Add all the adjusted EPS together and divide 10 will get our e10.


ResMed  (FRA:RMEA) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

ResMed's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=20.00/0.46
=43.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of ResMed was 102.35. The lowest was 33.33. And the median was 51.11.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


ResMed E10 Related Terms

Thank you for viewing the detailed overview of ResMed's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


ResMed Business Description

Address
9001 Spectrum Center Boulevard, San Diego, CA, USA, 92123
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

ResMed Headlines

No Headlines